Alkermes plc announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. The final dataset from the phase 1/2 ARTISTRY-1 clinical trial, evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA), will be shared in an oral presentation. In addition, trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling studies ARTISTRY-6 and ARTISTRY-7 will be presented.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.1 USD | -1.99% | +0.37% | -13.12% |
May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
May. 01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.12% | 4.08B | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Alkermes plc Announces Four Abstracts Accepted for Presentation At the 2022 American Society of Clinical Oncology Annual Meeting